Today: 7 February 2026
Subscribe
Browse Category

NASDAQ:CYTK News 21 December 2025 - 1 January 2026

Cytokinetics (CYTK) stock ends 2025 higher as Myqorzo launch nears — what’s next

Cytokinetics (CYTK) stock ends 2025 higher as Myqorzo launch nears — what’s next

NEW YORK, January 1, 2026, 07:56 ET — Market closed Cytokinetics, Incorporated (CYTK.O) shares rose $2.17, or 3.5%, to $63.54 in the last trading session of 2025, after swinging between $60.93 and $64.43 on volume of about 1.85 million shares. U.S. markets were shut on Thursday for the New Year’s Day holiday. Yahoo Finance The year-end move keeps focus on the company’s pivot from clinical-stage developer to commercial operator, with investors looking for hard signals on pricing and early demand. For drug developers, the first few weeks of launch execution can reset expectations quickly. Cytokinetics has said Myqorzo is expected
1 January 2026
····
Cytokinetics stock jumps today as CYTK traders focus on Myqorzo launch and insider filing

Cytokinetics stock jumps today as CYTK traders focus on Myqorzo launch and insider filing

NEW YORK, December 31, 2025, 14:52 ET — Regular session Cytokinetics, Incorporated shares rose 3.7% to $63.63 in afternoon trading on Wednesday, after touching $64.40 earlier in the session. The stock traded as low as $60.87, while the S&P 500 tracker and Nasdaq 100 fund were both down about 0.4% to 0.5%. The move matters because Cytokinetics is nearing its first U.S. commercial launch after winning FDA approval for Myqorzo (aficamten) this month. The company has said the drug should be available in the U.S. in the second half of January and will be distributed under a REMS program —
31 December 2025
··
Cytokinetics (CYTK) Stock Hits 52-Week High as FDA Approval of Myqorzo Triggers Analyst Price-Target Hikes

Cytokinetics (CYTK) Stock Hits 52-Week High as FDA Approval of Myqorzo Triggers Analyst Price-Target Hikes

Cytokinetics, Incorporated (NASDAQ: CYTK) surged on Monday, December 22, 2025, extending a sharp rally that followed the company’s first-ever U.S. drug approval. Shares traded around $69.68 in the session, up roughly 11% from the prior close, after reaching an intraday high near $70.86—a move that pushed the biotech to fresh 52-week highs and re-focused Wall Street on the commercial potential of its newly approved heart drug, Myqorzo (aficamten). Investing.com The immediate catalyst is straightforward: the U.S. Food and Drug Administration approved Myqorzo on December 19, 2025 for adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM). But the market reaction on December
22 December 2025
·
Biotechnology Stocks Week Ahead (Dec. 22–26, 2025): BioMarin–Amicus Deal, Cytokinetics FDA Win, IPO Filings, and Drug-Price Policy Risks

Biotechnology Stocks Week Ahead (Dec. 22–26, 2025): BioMarin–Amicus Deal, Cytokinetics FDA Win, IPO Filings, and Drug-Price Policy Risks

Biotechnology stocks head into the Christmas-shortened trading week with fresh momentum—and plenty for investors to digest—after a dense run of catalysts between December 19 and December 21, 2025. In the span of 48 hours, the sector saw a major rare-disease acquisition, a closely watched FDA approval in cardiology, IPO paperwork from both biotech and medtech, and a sweeping wave of U.S. drug-pricing headlines that could reshape sentiment into 2026. Investopedia+4Reuters+4Reuters+4 The setup matters because next week’s market structure will be unusual: U.S. stock markets are scheduled to close early on Wednesday, December 24 (1:00 p.m. ET) and remain closed on
21 December 2025
·····

Stock Market Today

Broadcom Stock Gets a Google AI Spend Lift as Jefferies Sees 60% Upside

Broadcom Stock Gets a Google AI Spend Lift as Jefferies Sees 60% Upside

7 February 2026
Google raised its 2026 capital expenditure forecast to $175 billion–$185 billion, with most spending expected on data-center chips. Broadcom shares rose about 2% after the announcement, while Nvidia and AMD slipped. Jefferies reiterated a buy rating on Broadcom, maintaining a $500 price target, implying a 62% upside from Wednesday’s close.
No $2,000 IRS stimulus check is coming in February 2026 — but Trump’s tariff-check talk keeps the rumors alive

No $2,000 IRS stimulus check is coming in February 2026 — but Trump’s tariff-check talk keeps the rumors alive

7 February 2026
The IRS has not announced new federal stimulus payments for February 2026, and Congress has not approved fresh checks. Trump told NBC he is considering $2,000 tariff rebate checks but has not committed, saying any payout would likely come later in 2026. The IRS warns taxpayers to ignore texts and emails about “stimulus payments” and verify notices through official channels.
Go toTop